Cancer cell death strategies by targeting Bcl-2's BH4 domain.
Anti-apoptotic Bcl-2
Apoptosis
BIRD-2
Calcium signaling
Lymphoma
Small molecules
Journal
Biochimica et biophysica acta. Molecular cell research
ISSN: 1879-2596
Titre abrégé: Biochim Biophys Acta Mol Cell Res
Pays: Netherlands
ID NLM: 101731731
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
18
12
2020
revised:
19
01
2021
accepted:
20
01
2021
pubmed:
8
2
2021
medline:
18
9
2021
entrez:
7
2
2021
Statut:
ppublish
Résumé
The Bcl-2-family proteins have long been known for their role as key regulators of apoptosis. Overexpression of various members of the family is associated with oncogenesis. Its founding member, anti-apoptotic Bcl-2 regulates cell death at different levels, whereby Bcl-2 emerged as a major drug target to eradicate cancers through cell death. This resulted in the development of venetoclax, a Bcl-2 antagonist that acts as a BH3 mimetic. Venetoclax already entered the clinic to treat relapse chronic lymphocytic leukemia patients. Here, we discuss the role of Bcl-2 as a decision-maker in cell death with focus on the recent advances in anti-cancer therapeutics that target the BH4 domain of Bcl-2, thereby interfering with non-canonical functions of Bcl-2 in Ca
Identifiants
pubmed: 33549704
pii: S0167-4889(21)00037-9
doi: 10.1016/j.bbamcr.2021.118983
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
BCL2 protein, human
0
BIRD-2 peptide
0
Peptides
0
Proto-Oncogene Proteins c-bcl-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
118983Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.